No significant improvement in therapy of pancreatic cancer has been reported over the last 25 y, underscoring the urgent need for new alternative therapies. Here, we coupled a radioisotope, 188 Rhenium, to an attenuated (at) live Listeria monocytogenes (Listeria at ) using Listeria-binding antibodies, thus creating a unique radioactive Listeria at (RL). We then demonstrated in a highly metastatic pancreatic mouse tumor model (Panc-02) that RL delivered radioactivity to the metastases and less abundantly to primary tumors in vivo, without harming normal cells. This result was possible because Listeria at was efficiently cleared by the immune system in normal tissues but not in the heavily immune-suppressed microenvironment of metastases and primary tumor. Multiple treatments with low doses of the RL resulted in a dramatic decrease in the number of metastases (∼90%) compared with control groups in the Panc-02 model. This is the first report of using live attenuated bacteria delivering a highly radioactive payload to the metastases, resulting in killing tumor cells in vivo without harming normal cells. The nontoxic RL treatment is attractive for clinical development as a therapy to prevent pancreatic cancer recurrence and metastases. P ancreatic ductal adenocarcinoma, synonymous to pancreatic cancer, is the fourth leading cause of cancer deaths. The socalled silent killer is characterized by its metastatic behavior before the primary tumor can be detected, resulting in a 5-y survival rate of only 4%. Current cancer treatments-i.e., surgery followed by radiation and/or chemotherapy-are ineffective, particularly against liver metastases. Gemcitabine and erlotinib, Food and Drug Administration-approved drugs for pancreatic cancer treatment, improve median survival by ∼6 mo in patients with advanced-stage disease (1-3), emphasizing the need for new alternative therapies for metastatic pancreatic cancer.
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For any anticancer approach to be effective, it needs to target metastases and/or remaining tumor cells after primary therapeutic intervention. Indeed, in most cases, cancer therapy is now highly effective in eradicating primary tumors through combinations of surgery, radiation, and adjuvant therapy. The reason that cancer remains such a formidable health problem is its capacity to recur in the form of widespread metastases, often with a fatal consequence. In a previous study, we found that a highly attenuated bacterium, Listeria monocytogenes (Listeria at ), which was originally used to deliver tumor-associated antigens into antigen-presenting cells, also infected tumor cells in vitro and in vivo (4) . Although Listeria at was efficiently cleared by the immune system in the normal tissues within 3-5 d, immune suppression in the tumor microenvironment allowed these bacteria to accumulate in metastases and primary tumors and to kill tumor cells through high levels of reactive oxygen species (ROS) (4) . Based on these results we hypothesized that Listeria at could be used to deliver anticancer agents, such as therapeutic radionuclides (emitting cytocidal radiation such as beta-particles), specifically to the microenvironment of metastases and primary tumors and into tumor cells.
Targeted radionuclide therapy has proven successful in the treatment of several types of cancer and currently employs radiolabeled small molecules, monoclonal antibodies (Abs), peptides, and other tumor-targeting vehicles (5) . The radioactive particles emitted by the radionuclides physically destroy the cancerous cells, and such therapies are not subject to multidrug-resistance mechanisms. There have been attempts to use targeted radionuclide therapy in form of radiolabeled tumor-specific Abs (radioimmunotherapy) for treatment of pancreatic cancer. However, radioimmunotherapy of pancreatic cancer has shown very modest results both preclinically (6) (7) (8) and in cancer patients with unresectable liver metastases (9) . Obviously, new choices of targeting vehicles are needed to make targeted radionuclide therapy successful in the treatment of pancreatic cancer. In this regard, Listeria at provides an attractive system for the delivery of radionuclides into the microenvironment of metastases and primary tumors. Here we show that live attenuated Listeria at coupled with radionuclide 188 Rhenium ( 188 Re) is highly effective, particularly against metastases, in a mouse model of pancreatic cancer (Panc-02 model) without appreciable side effects.
Results

Listeria
at Multiplies in Metastases but Poorly in Primary Tumors and Not in Normal Tissues. Metastatic Panc-02 tumors were generated in C57BL/6 mice. Subsequently, the tumor-bearing mice were injected with Listeria at [0.5 × 10 7 colony-forming units (cfus)] intraperitoneally (i.p.), and their organs, primary tumors, and metastases were analyzed for the presence of live Listeria at at various time intervals (1, 3, and 7 d after injection of the bacteria). As demonstrated in Fig. 1A , Listeria at multiplied in the metastases between days 1 and 3, but not in normal tissues such as the spleen. Although a strong accumulation of Listeria at was found in the primary tumors on day 1, no multiplication of Listeria at was observed between days 1 and 3 or between days 3 and 7. Therefore, we also analyzed earlier time intervals (3, 6 , and 72 h after injection of the bacteria) and found that Listeria at did multiply to some degree between 3 and 6 h, but the number of cfu of Listeria at decreased between 6 and 72 h in the primary tumor (Fig. 1B) . The presence of Listeria at in metastases, primary tumor, and tissues was confirmed by confocal microscopy (Fig. 1C) . That Listeria at could also multiply inside tumor cells is demonstrated here in vitro after 1, 3, and 6 h of incubation with the Listeria at ( Fig. 1D ) and confirmed by confocal microscopy (Fig. 1E) . Although after 1-and 3-h incubation usually one bacterium was found per tumor cell, after 6 h we detected four to six Listeria at bacteria per tumor cell. Because gentamicin was used in the medium, the extracellular Listeria at bacteria were dead, but the intracellular bacteria were alive. Special attention in this Panc-02 mouse tumor model was given to the pancreas. We found that the pancreas of tumor-bearing mice was heavily infiltrated with the Panc-02 tumor cells (Fig.  S1A ). Listeria at strongly multiplied in the pancreas infiltrated with the tumor cells, but not in the pancreas of mice without tumor cells (Fig. S1C ), and this finding was confirmed by confocal microscopy (Fig. S1B ). was altered by the radioactivity. For this purpose, Panc-02 cells were incubated with the various RLs for 1 h, followed by gentamicin treatment for 1 h, and then lysed and plated on agar. Interestingly, the infection rates of RL-120 and -200 for Panc-02 cells were significantly higher than of Listeria at alone, whereas there was no significant difference between the Listeria at -Ab complex and Listeria at alone (Fig. 2C ). This result suggests that the higher infection rate of RL might be caused by the radioactivity and not by the Ab. In summary, the highest infection rate of the Panc-02 cells was observed for RL-200. Based on these results, we chose to use a dose of 200 μCi of RL in all further experiments. Finally, we also tested the stability of the RL complex in serum and PBS. RL was incubated in serum or PBS for 0, 1, and 3 h at 37°C and showed very low dissociation grades of RL-i.e., radioactive counts were found in the supernatant of the serum varying between 0.1% and 0.6% of the baseline radioactivity, and this result was not significantly different from the radioactivity in the supernatant of PBS (Fig. 2D) . Preliminary experiments demonstrated that the injection of mice with a high dose of Listeria at (0.5 × 10 7 cfu) once a week led to clearance of most of the Listeria at bacterial cells between days 3 and 7 (Fig. 1A) . However, for therapy, it is important to have a low level of live Listeria at bacterial cells that can continuously deliver the radioactivity into the tumor cells, without inducing listeriosis. Therefore, we developed a unique treatment protocol for the RL. Mice were challenged with 2 × 10 6 Panc-02 tumor cells in the mammary fat pad on day 0. This process resulted in a small primary tumor in the mammary fat pad palpable at 5-7 d, and metastases were found predominantly in the portal liver (area of portal vein in the liver) and throughout the liver, accompanied by a strong production of ascites within 21 d. Three days after tumor cell injection, mice were injected i.p. daily with 10 4 cfu of RL/500 μL of saline (group 1), 10 4 cfu of Listeria at /500 μL of saline (group 2), 200 μCi of 188 Re/500 μL of saline (group 3), or 500 μL of saline (group 4) on days 3-9, followed by a rest period of 1 wk, followed by four injections with the same dose on days [16] [17] [18] [19] . All mice were euthanized on day 21 and analyzed for metastases and tumors. Although most of the metastases were predominantly present in the portal liver, metastases were also found in the pancreas, diaphragm, kidney, and mesenteric lymph nodes (MLNs). In addition, these metastases were eliminated by RL treatment. The metastases in Fig. 3A were a mixture of all metastases, but predominantly represent liver sites. RL decreased the number of metastases by ∼90% and Listeria at alone by ∼50%, compared with the saline group or 188 Re (Fig. 3A ). An example of the metastases in the portal liver of each group is shown in Fig. 3B . The effect on primary tumors was less pronounced but still significant. RL reduced the tumor weight by ∼64% and the Listeria at by ∼20% compared with the saline group. In the same experiment, we measured the amount of radioactivity that accumulated in metastases and normal tissues after the 11 treatments. We found that the radioactivity accumulated selectively in the metastases and much less in the primary tumors and normal organs-i.e., the radioactivity in the metastases was 4-to 15-fold higher compared with all other organs, except liver and kidneys (Fig. 3C) . The radioactivity levels found in liver and kidneys were comparable to the metastases. We also measured the radioactivity as well as live Listeria at 1 wk after the last treatment. It appeared that by that time point the radioactivity was not measurable anymore, and all Listeria at were cleared by the immune system. Using medical internal radiation dose formalism, we have estimated that the dose delivered to the tumor by RL was ∼30 Gy, which is within a tumoricidal range for internal radionuclide therapy (5). (11) (12) (13) , the combination of Listeria at and radioactivity has never been tested for its safety in vivo. Therefore, we performed various experiments aimed at testing RL safety, such as biodistribution of RL, free 188 Re, and Listeria at ; pathology; and liver functions.
First, we measured the biodistribution of RL in all mouse tissues with and without Panc-02 tumors on days 1 and 7 after one i.p. administration of a high dose of RL (0.5 × 10 7 cfu) or with a comparable dose of free 188 Re. Day 1 was chosen to determine the biodistribution of RL in all tumor and normal tissues, and day 7 was chosen because we expected that, based on the half-life of 188 Re (17 h), the radioactivity should be below the detection level, which is important from a clinical point of view. One day after injection, all tissues were collected and measured for gamma radiation. Here, we demonstrate that radioactivity was present in all organs, including metastases and tumors on day 1 (Table 1) . However, kidneys and liver contained much higher levels of radioactivity than the other organs or tumors and metastases (Table 1) . A similar pattern was observed in mice without tumors, but lower levels of radioactivity were measured (Table 1) . Free 188 Re was not detectable in all tissues of mice with or without tumors ( Table 1) . As expected, on day 7, no radioactivity was measurable in any of the tissues of mice with or without tumors because of the short half-life of 188 Re, i.e., 17 h (Table 1 ). Second, we tested the biodistribution and clearance pattern of Listeria at alone in mice, with or without Panc-02 tumors, on days 1, 3, and 7 after one i.p. injection of the high dose of Listeria at (0.5 × 10 7 cfu). These three time intervals were selected because Listeria at bacteria are able to multiply at different times in vivo as shown in Fig. 1 A and B , in contrast to the radioactivity that will only decrease after injection. On day 1, Listeria at cfus were predominantly cultured from metastases and primary tumors ( Table  2) . Listeria at multiplied strongly in the metastases between days 1 and 3, but not in the primary tumors, and the cfu of Listeria at decreased in both metastases and tumor between days 3 and 7. We also analyzed the biodistribution and clearance at earlier time points (3, 6 , and 72 h) and showed that the Listeria at strongly multiplied in the metastases at all time points, but only to some degree in the primary tumors between 3 and 6 h (Table S1) . A similar pattern of biodistribution of the Listeria at cfu was observed with Listeria at Ab (Table S2 ). In addition to the multiplication of Listeria at in the metastases (less in the tumors), it cannot be excluded that some Listeria at from the normal tissues migrated to the metastases and tumor tissues. Listeria at again did not multiply in normal tissues, with the exception of the liver infiltrated with tumor cells. Listeria at cfus were also found in the spleen at much reduced numbers, and some Listeria at cfus were cultured from the rest of the tissues. On day 7, Listeria at was cleared from all normal tissues, including the liver, whereas bacteria were still present in metastases and primary tumor, although at much lower levels than on day 1 or 3. In the mice without tumors, the cfu of Listeria at were predominantly cultured from the spleen on day 1, but Listeria at did not multiply in normal tissues, and Listeria at bacterial cells were completely cleared from all tissues on day 7 (Table 2) .
Finally, all tissues were analyzed for damage by histopathology after the 11 RL treatments in mice with pancreatic cancer. We were particularly interested in the normal liver and kidney because of the high radioactivity found in these tissues. One week after the last treatment, we observed no pathological damage by RL, 188 Re, or Listeria at in the normal tissues, including liver or The results were averaged and subjected to statistical analysis. All groups were compared with the Listeria at group. P < 0.05 is statistically significant (ANOVA). The number of Listeria at cfu was determined per 10 6 cells. (D) The stability of RL in serum was analyzed by incubating RL with serum or PBS (negative control) at 37°C. After 0, 1, and 3 h, the RL bacteria were centrifuged, and the supernatant was analyzed for radioactive counts. The dissociation grade (percent) of the RL complex was determined by dividing free radioactivity in the supernatant and baseline radioactivity (10 7 cpm). Data shown are the average of two experiments. P < 0.05 is significant (unpaired t test). The error bars represent SEM.
kidney (Table S3) . We also analyzed the liver function by measuring for aspartate transaminase (AST) and alanine transaminase (ALT) in serum. One week after the last of 11 treatments with RL, Listeria at , free 188 Re, or saline, liver functions were not altered by RL, 188 Re, or Listeria at (Table S4) .
Discussion
Unresectable liver metastases in pancreatic cancer patients are currently managed with cytotoxic treatment, which extends survival time by 6 mo only (1-3). Metastases are chemoresistant and cannot be removed by surgery or external radiation. In the present study, we demonstrate, in a highly aggressive mouse model of pancreatic cancer, that delivery of radionuclide 188 Re by a live attenuated Listeria at bacterium resulted in a dramatic reduction in the number of metastases, compared with the control groups, correlating with an accumulation of ionizing radiation-emitting 188 Re in the metastases, without side effects. It is known that Listeria has various mechanisms to infect cells in vitro and in vivo. Listeria can infect cells directly, such as macrophage-like cells through phagocytosis, or it can infect cells through a cell-to-cell spread mechanism characteristic for Listeria (14) . In the present study, we found that Listeria at directly infected pancreatic tumor cells (Fig. 1 D and E) , and in an earlier study, it was found to also infect breast tumor cells (4) . In addition, we found that Listeria at infected myeloid-derived suppressor cells (MDSCs), and when injected into the tail vein of Panc-02 tumor-bearing mice, these MDSCs delivered the Listeria at bacteria selectively to the metastases, where it could spread from cell to cell without being eliminated by the immune system; however, it was very poorly delivered to normal tissues such as the spleen (Fig. S2) .
Because RL exhibits several mechanisms to kill tumor cells, we questioned which mechanism contributed the most to the strong effect on metastases in vivo. Based on a previous study in a metastatic breast tumor model (4T1) that received one preventive followed by two therapeutic treatments with Listeria at4 , we expected that Listeria at -activated T cells should kill tumor cells in vivo in the Panc-02 model as well, because infected tumor cells become a target for Listeria at -activated T cells and natural killer (NK) cells. However, after the 11 therapeutic treatments with low-dose RL in this Panc-02 model, CD8 T-cell (and NK cell) responses in vivo were weak and not statistically significant from the saline group (Fig. S3) , suggesting a minor role of Listeria at -activated immune responses in tumor cell destruction in vivo. As shown in this study, Listeria at and RL infect Panc-02 cells (although not all of the tumor cells), and both can kill tumor cells through high levels of ROS (4, 15) . In addition, extracellular Listeria at or RL can kill tumor cells as well-i.e., through Listeriolysin O (LLO) secreted by Listeria at inducing high levels of ROS inside the tumor cells (4) or through the crossfire effect of radioactivity generated by 188 Re (15) . Although both had a significant effect on the metastases, the effect of RL was significantly higher than of Listeria at alone. Based on these results, we concluded that the cytocidal 188 Re radiation mostly and Listeria at -induced ROS less abundantly (but significantly) contributed to the destruction of tumor cells in the metastases, whereas Listeria at -activated CD8 T and NK cells in vivo played a minor role in tumor cell destruction in this Panc-02 model.
A smaller effect of RL was observed on primary tumors. Radiation-induced damage is most effective in highly proliferating cells. Although tumor cells in the metastases are highly proliferating, in the primary tumors of this Panc-02 model, the tumor cells were largely dormant, and therefore metastases are a much better target for radiation-induced kill than primary tumors. To prove that radiation-induced damage is considerably less in nondividing cells than in highly proliferating cells, we tested the damaging effect of RL in cultures of Panc-02 cells with a high Re was measured in all tissues of RL-treated mice 1 d after the last treatment by a gamma counter. The radioactive counts in each tissue were compared with the counts in the metastases using unpaired t test. P < 0.05 is statistically significant. The error bars represent SEM. C57Bl6 mice with or without Panc-02 tumors (Tum) and metastases (Mets) were injected with 0.5 × 10 7 cfu of RL or 188 Re and euthanized on days 1 and 7. The number of radioactive counts was determined in various tissues in triplicates, and the results of two experiments were averaged. n = 5 mice per experiment. The radioactivity by RL on day 7 and by 188 Re on days 1 and 7 was below the detection limit and therefore not shown. GI, gastrointestinal; LN, lymph nodes.
(nonproliferating) and low (highly proliferating) density in vitro. After RL treatment, only 25% of the Panc-02 tumor cells at low density and 53% of Panc-02 cells at high density were alive the next day (Fig. S4) . These results support the lesser effect of RL on the dormant tumors compared with the highly proliferating metastases.
The dramatic effect of RL on the metastases in the Panc-02 model was repeatedly found without inducing severe side effects on normal tissues. However, the radioactivity was high in the metastases and in liver and kidney. One could argue that the RL complex is unstable, but stability assays of RL in serum and PBS as control (0, 1, and 3 h at 37°C) showed that the RL complex was highly stable and did not dissociate in the serum. Most likely, the radiolabeled Listeria at are killed by the immune system and metabolized by the body. The processed radiolabeled proteins will end up in the liver and kidneys as the sites of their metabolism and excretion, respectively. Such a phenomenon is well known in radioimmunotherapy (15) . Of clinical importance, neither Listeria at nor radioactivity was detected in normal or tumor tissues 1 wk after the last treatment. Despite the accumulation of radioactivity in the liver and kidneys, pathological examination revealed practically no histologically apparent side effects in normal tissues, and liver functions, such as AST and ALT, appeared to be unaltered. This finding raises the question as to why RL, when accumulated in metastases as well as in normal kidneys and liver, destroys tumor cells, but not cells in normal kidney and liver. One possible explanation is that radiation-induced irreparable DNA damage is much higher for proliferating cells, like metastases, than in nondividing normal tissues. As mentioned above, a lesser effect of RL and Listeria at was observed on primary tumors, because the proliferation of these dormant Panc-02 tumors is poor compared with the metastases. Finally, Listeria at survives and replicates better, and produce higher levels of ROS in a hypoxic environment (16) , like the metastases in this model.
The highly attenuated Listeria at used in this study is different from wild-type Listeria, in the sense that the latter multiplies in hepatocytes in the liver or epithelial cells of the gastrointestinal tract (17, 18) , whereas Listeria at does not. In support of these results, we have already shown that a high dose of Listeria at or 188 Re is less toxic in humans than chemotherapy (11) (12) (13) . Currently, other Listeria constructs are available with reduced pathogenicity and used for different approaches. One example is the killed but metabolically active Listeria strain of Brockstedt et al. (19) . This strain has reduced pathogenicity by deleting the actA (required for cell to cell spread, characteristic for Listeria) and the UV-sensitive uvrAB genes, without losing its potency to activate CD4 and CD8 T-cell responses. Another Listeria strain has been developed by Goebel and colleagues (20) , which has been deleted for internalins InlA and InlB (ligands for entry receptors), but expressing Stapylococcus aureus antigen that can bind IgG Abs such as Herceptin and then induce internalization of the Listeria into Her2/neu-expressing breast tumor cells. Such an approach is highly promising, and a similar approach could be used to deliver radioisotopes with improved efficiency into tumor cells. In addition, others have shown the potential of bacteria for delivery of anticancer agents into tumor cells (21, 22) .
In conclusion, our data demonstrate that live attenuated bacteria can deliver radioactivity to the metastases of pancreatic cancer in vivo, resulting in killing tumor cells without having severe side effects. Such an approach might start a unique era in the treatment of metastases from pancreatic cancer.
Materials and Methods
Mice. Normal female C57BL/6 mice aged 3 mo were obtained from Charles River and maintained in the animal husbandry facility of the Albert Einstein College of Medicine according to the Association for Assessment and Accreditation of Laboratory Animal Care guidelines, and according the guidelines of the Albert Einstein Institute for Animal Studies. All mice were kept under Biological Safety Level 2 conditions as required for Listeria at treatments.
Cells and Cell Culture. The Panc-02 cell line is highly tumorigenic and metastatic and was derived in 1984 from a methylcholanthrene-induced ductal adenocarcinoma growing in a C57BL/6 female mouse (23) (provided by Chandan Guha, Albert Einstein College of Medicine). The Panc-02 cells were cultured in McCoy's medium supplemented with 10% (vol/vol) FBS, glutamine (2 mM), nonessential amino acids, sodium pyruvate (1 mM), Hepes (10 mM), and penicillin/streptomycin (100 U/mL). Re to the tumor microenvironment. The Listeria at plasmid pGG-34 expresses the positive regulatory factor A (prfA) and LLO (25) . prfA regulates the expression of other virulence genes and is required for survival in vivo and in vitro (25) . The background strain XFL-7 lacks the prfA gene and retains the plasmid in vitro and in vivo. The coding region for the C-terminal part of the LLO (cytolytic domain that binds cholesterol in the membranes) protein in the plasmid has been deleted, but Listeria at is still able to escape the vacuole (25) . Mutations have been introduced into the prfA gene and the remaining LLO (expressed by the pGG34 vector), which further reduced the pathogenicity of the Listeria at25 .
188
Re, Anti-Listeria Abs, and Making RL. C57BL/6 mice with or without Panc-02 tumors (Tum) and metastases (Mets) were injected with 0.5 × 10 7 cfu of Listeria at and euthanized on days 1, 3, and 7. The number of Listeria at cfu was determined in various tissues, and the results of two experiments were averaged. n = 5 mice per experiment. bdl, below detection limit; GI, gastrointestinal; LN, lymph nodes.
